{"id":4807,"date":"2023-06-13T18:53:37","date_gmt":"2023-06-13T09:53:37","guid":{"rendered":"https:\/\/hbio.jp\/news\/?p=4807"},"modified":"2023-06-14T11:25:37","modified_gmt":"2023-06-14T02:25:37","slug":"20230613-2","status":"publish","type":"post","link":"https:\/\/hbio.jp\/news\/en\/2023\/06\/13\/20230613-2\/","title":{"rendered":"Hirotsu Bio Science Signs Memorandum of Understanding with Global Health Equity Fund, Aims to Expand Overseas Deployment of N-NOSE\u00ae"},"content":{"rendered":"

Hirotsu Bio Science Inc. (Headquarters: Chiyoda-ku, Tokyo, Representative Director: Takaaki Hirotsu) has signed a memorandum of understanding with the Global Health Equity Fund (GHEF), an impact fund that aims to support and create impacts that lead to solutions to global health issues, to expand N-NOSE overseas to countries with underdeveloped healthcare systems.

<\/p>\n\n\n\n

The Global Health Equity Fund (GHEF), established through a partnership between the WHO Foundation and venture capital firm OurCrowd, is an impact investment fund that aims to promote the permeation of innovative medical treatments that utilize groundbreaking technologies to improve the health conditions of people living in vulnerable low- and middle-income countries and regions, and to bring about healthier lives for humanity on a global scale while pursuing profitability.

<\/p>\n\n\n\n

This signing ceremony ratified the agreement between Hirotsu Bio Science and the GHEF to expand the overseas deployment of N-NOSE to low- and middle-income countries, as agreed upon in a meeting on May 11th.

<\/p>\n\n\n\n

GHEF General Partner Dr. Morris Laster and the WHO Foundation’s Chief Executive Officer Anil Soni and Chief Impact Investment Officer Geetha Tharmaratnam visited Japan as representatives of the GHEF. Masayoshi Hirose, General Manager of Healthcare Dept., Infrastructure & Healthcare Division of Sojitz Corporation, who are cooperating in the overseas expansion of N-NOSE, attended the ceremony.

<\/p>\n\n\n\n

\"Masayoshi
Masayoshi Hirose, General Manager of Healthcare Dept. (Sojitz)\u3001Morris Laster, OurCrowd General Partner & GHEF General Partner (OurCrowd)\u3001
Takaaki Hirotsu, President & CEO (Hirotsu Bio Science)\u3001Anil Soni, CEO and Geetha Tharmaratnam, Chief Impact Investment Officer (WHO Foundation) <\/figcaption><\/figure>\n\n\n\n

\u25a0Summary of the memorandum of understanding:<\/strong><\/p>\n\n\n\n

Hirotsu Bio Science, with its innovative cost-effective, comprehensive, and high-precision cancer testing, aims to support the overseas expansion of N-NOSE to low- and middle-income countries and contribute to the resolution of global health issues.

<\/p>\n\n\n\n

  1. 1. Advice on N-NOSE product improvement and cost optimization for new markets<\/li>
  2. 2. Identify promising markets for Lower Middle Income Countries (LMICs)   <\/li>
  3. 3. Provide guidance on regulatory pathways in target countries<\/li>
  4. 4. Leverage the WHO Foundation’s network to provide third-party distributors in LMICs target countries.  Provide access and drive market entry and expansion<\/li>
  5. 5. Identify key regulatory stakeholders in target markets and LMICs<\/li>
  6. 6. Preparation of financial forecasts for various market entry scenarios<\/li>
  7. 7. Establish pilot programs and local partnerships for early adoption<\/li>
  8. 8. Providing pricing strategies for diverse LMICs markets<\/li>
  9. 9. Leverage the relationship between GHEF and the WHO Foundation to increase credibility and awareness <\/li>
  10. 10. Response to local medical insurance systems<\/li>
  11. 11. Secure additional funding from local governments and NGOs<\/li>
  12. 12. Access to Global Key Opinion Leader (KOLs)

    <\/li><\/ol>\n\n\n\n
    \n\n\n\n

               
    \u2192Download details \/ PRESS RELEASE\uff08PDF\uff09<\/a>

    <\/p>\n\n\n\n

    Press Inquiries<\/strong>
    Hirotsu Bio Science Inc.   press@hbio.jp <\/p>","protected":false},"excerpt":{"rendered":"

    Hirotsu Bio Science Inc. (Headquarters: Chiyoda-ku, Tokyo, Representative Director: Takaaki Hirotsu) has signe […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"4807","footnotes":""},"categories":[2],"tags":[],"class_list":["post-4807","post","type-post","status-publish","format-standard","hentry","category-news","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/4807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/comments?post=4807"}],"version-history":[{"count":30,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/4807\/revisions"}],"predecessor-version":[{"id":4874,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/4807\/revisions\/4874"}],"wp:attachment":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/media?parent=4807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/categories?post=4807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/tags?post=4807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}